Online Exclusive Article

CAR T-Cell Therapy Effects: Review of Procedures and Patient Education

Holly McConville

Megan Harvey

Colleen Callahan

Laura Motley

Heather Difilippo

Claire White

CTL019 chimeric antigen receptor, adoptive cellular immunotherapy, clinical trial
CJON 2017, 21(3), . DOI: 10.1188/17.CJON.E79-E86

Background: Chimeric antigen receptor (CAR) T-cell therapy is a cellular immunotherapy that redirects the killing activity of T cells to fight tumor cells. CD19 CAR T-cell therapies have demonstrated high rates of complete response in clinical trials in patients with relapsed or refractory B-cell malignancies and have been associated with on-target side effects.

Objectives: This article describes educational opportunities for patients and families during the CAR T-cell therapy procedure, highlighting specific points where education by nurses is critical for safety and protocol adherence.

Methods: Current literature on CAR T-cell therapy was reviewed and supported by the authors’ professional experiences.

Findings: CAR T-cell therapy is a novel treatment, and repetition of information and building the knowledge base of patients and families is important. The role of nurses in educating patients about the side effects of CAR T-cell therapy is critical for the safety and psychological well-being of patients.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.